BR112022000925A2 - Nanopartículas de rna multilamelares - Google Patents

Nanopartículas de rna multilamelares

Info

Publication number
BR112022000925A2
BR112022000925A2 BR112022000925A BR112022000925A BR112022000925A2 BR 112022000925 A2 BR112022000925 A2 BR 112022000925A2 BR 112022000925 A BR112022000925 A BR 112022000925A BR 112022000925 A BR112022000925 A BR 112022000925A BR 112022000925 A2 BR112022000925 A2 BR 112022000925A2
Authority
BR
Brazil
Prior art keywords
methods
nanoparticles
subject
multilamellar
nucleic acid
Prior art date
Application number
BR112022000925A
Other languages
English (en)
Portuguese (pt)
Inventor
Carlos Rinaldi
Duane Mitchell
Elias Sayour
Ruben Mendez-Gomez Hector
Original Assignee
Univ Florida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Florida filed Critical Univ Florida
Publication of BR112022000925A2 publication Critical patent/BR112022000925A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0033—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being non-polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
BR112022000925A 2019-07-19 2020-07-17 Nanopartículas de rna multilamelares BR112022000925A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962876440P 2019-07-19 2019-07-19
US201962877598P 2019-07-23 2019-07-23
US201962884983P 2019-08-09 2019-08-09
US201962933326P 2019-11-08 2019-11-08
PCT/US2020/042606 WO2021016106A1 (en) 2019-07-19 2020-07-17 Multilamellar rna nanoparticles

Publications (1)

Publication Number Publication Date
BR112022000925A2 true BR112022000925A2 (pt) 2022-05-17

Family

ID=74193752

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022000925A BR112022000925A2 (pt) 2019-07-19 2020-07-17 Nanopartículas de rna multilamelares

Country Status (8)

Country Link
US (1) US20220287969A1 (https=)
EP (1) EP3999034A4 (https=)
JP (2) JP7783628B2 (https=)
KR (1) KR20220035434A (https=)
AU (1) AU2020316335B2 (https=)
BR (1) BR112022000925A2 (https=)
CA (1) CA3144388A1 (https=)
WO (1) WO2021016106A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230346700A1 (en) * 2020-02-19 2023-11-02 University Of Florida Research Foundation, Incorporated Multilamellar RNA Nanoparticles and Methods of Sensitizing Tumors to Treatment with Immune Checkpoint Inhibitors
CA3174187A1 (en) * 2020-04-01 2021-10-07 University Of Florida Research Foundation, Incorporated Multilamellar rna nanoparticle vaccine against sars-cov-2
JP2024517287A (ja) * 2021-05-07 2024-04-19 ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド Ｃａｒ ｔ細胞療法の方法
WO2024263713A1 (en) * 2023-06-21 2024-12-26 University Of Florida Research Foundation, Incorporated Materials and methods of using proinsulin mrna nanoparticles

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011112597A1 (en) * 2010-03-08 2011-09-15 Northeastern University Magnetic nanoplatforms for theranostic and multi-modal imaging applications
PL3586861T3 (pl) * 2011-06-08 2022-05-23 Translate Bio, Inc. Kompozycje nanocząstek lipidowych i sposoby dostarczania mrna
US10245229B2 (en) * 2012-06-08 2019-04-02 Translate Bio, Inc. Pulmonary delivery of mRNA to non-lung target cells
ITRM20120480A1 (it) * 2012-10-09 2014-04-10 Uni Degli Studi Camerino Nanoparticelle lipidiche multicomponenti e procedimenti per la loro preparazione.
CA2925047C (en) 2013-09-26 2021-03-23 Biontech Ag Rna decorated particles
US10583084B2 (en) 2014-06-26 2020-03-10 Ramot At Tel-Aviv University Ltd. Liposomal formulations for delivery of nucleic acids
WO2017062502A1 (en) * 2015-10-05 2017-04-13 The Regents Of The University Of Colorgo, A Body Corporate Lipoplexes formulated for catalytic delivery
CA3099519A1 (en) * 2018-05-08 2019-11-14 University Of Florida Research Foundation, Incorporated Magnetic liposomes and related treatment and imaging methods
WO2020037102A1 (en) * 2018-08-15 2020-02-20 University Of Florida Research Foundation, Inc. Methods of sensitizing tumors to treatment with immune checkpoint inhibitors
EP3849597A1 (en) * 2018-09-12 2021-07-21 University of Florida Research Foundation, Inc. Slow-cycling cell-rna based nanoparticle vaccine to treat cancer
EP4099988A4 (en) * 2020-02-05 2024-03-13 University of Florida Research Foundation, Incorporated Rna-loaded nanoparticles and use thereof for the treatment of cancer
US20230346700A1 (en) * 2020-02-19 2023-11-02 University Of Florida Research Foundation, Incorporated Multilamellar RNA Nanoparticles and Methods of Sensitizing Tumors to Treatment with Immune Checkpoint Inhibitors
CA3174187A1 (en) * 2020-04-01 2021-10-07 University Of Florida Research Foundation, Incorporated Multilamellar rna nanoparticle vaccine against sars-cov-2
WO2022140278A1 (en) * 2020-12-21 2022-06-30 University Of Florida Research Foundation, Inc. Multilamellar rna nanoparticle vaccine against cancer
JP2024517287A (ja) * 2021-05-07 2024-04-19 ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド Ｃａｒ ｔ細胞療法の方法
WO2023196232A1 (en) * 2022-04-04 2023-10-12 University Of Florida Research Foundation, Inc. Method of characterizing tumors

Also Published As

Publication number Publication date
CA3144388A1 (en) 2021-01-28
JP2022541586A (ja) 2022-09-26
EP3999034A4 (en) 2023-08-23
JP7783628B2 (ja) 2025-12-10
KR20220035434A (ko) 2022-03-22
WO2021016106A8 (en) 2022-02-10
AU2020316335A1 (en) 2022-02-17
AU2020316335B2 (en) 2026-04-02
JP2025138644A (ja) 2025-09-25
US20220287969A1 (en) 2022-09-15
EP3999034A1 (en) 2022-05-25
WO2021016106A1 (en) 2021-01-28

Similar Documents

Publication Publication Date Title
BR112022000925A2 (pt) Nanopartículas de rna multilamelares
Ashrafizadeh et al. (Nano) platforms in bladder cancer therapy: Challenges and opportunities
Peng et al. Tumor‐microenvironment‐responsive nanomedicine for enhanced cancer immunotherapy
Zhen et al. Biointerface‐engineered hybrid nanovesicles for targeted reprogramming of tumor microenvironment
Hadla et al. Exosomes increase the therapeutic index of doxorubicin in breast and ovarian cancer mouse models
Szatmári et al. Extracellular vesicles in modifying the effects of ionizing radiation
Liu et al. MicroRNA-200c delivered by solid lipid nanoparticles enhances the effect of paclitaxel on breast cancer stem cell
Chen et al. Mastering dendrimer self‐assembly for efficient siRNA delivery: from conceptual design to in vivo efficient gene silencing
Wang et al. Isothermal self-assembly of spermidine–DNA nanostructure complex as a functional platform for cancer therapy
Lv et al. Programmable DNA nanoflowers for biosensing, bioimaging, and therapeutics
MX2010005089A (es) Nanoparticulas tipo micela autoensambles para el suministro sistemico de genes.
Maheshwari et al. Recent advances in exosome-based nanovehicles as RNA interference therapeutic carriers
Kim et al. Consecutive targetable smart nanoprobe for molecular recognition of cytoplasmic microRNA in metastatic breast cancer
MX2022007680A (es) Nanoparticulas lipidicas para administracion de acidos nucleicos.
ZA202103233B (en) Lipid nanoparticle formulations
Ye et al. A novel targeted therapy system for cervical cancer: co-delivery system of antisense LncRNA of MDC1 and oxaliplatin magnetic thermosensitive cationic liposome drug carrier
PH12023500013A1 (en) Ionizable cationic lipids and lipi nanoparticles, and methods of synthesis and use thereof
BR112022019124A2 (pt) Composições e métodos para liberação de rna
MX2024009361A (es) Lipidos cationicos ionizables para nanoparticulas lipidicas
Chandler et al. Expanding structural space for immunomodulatory nucleic acid nanoparticles via spatial arrangement of their therapeutic moieties
JPWO2021022173A5 (https=)
BR112016023004A2 (pt) sirna, estrutura oligo rna de fita dupla, nanopartícula, composição farmacêutica e estrutura liofilizada para prevenir ou tratar fibrose ou doenças respiratórias contendo a mesma
Chen et al. Combining high-Z sensitized radiotherapy with CD73 blockade to boost tumor immunotherapy
Manikkath et al. Nanoparticulate strategies for the delivery of miRNA mimics and inhibitors in anticancer therapy and its potential utility in oral submucous fibrosis
MX2023009850A (es) Composiciones y metodos para la administracion de acidos nucleicos.

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]